News
C4X Discovery agrees licensing deal with Sanofi
UK-based drug discovery company C4X Discovery (C4XD) has signed an exclusive worldwide licensing agreement with Sanofi for access to its oral pre-clinical IL-17A inhibitor programme.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
UK-based drug discovery company C4X Discovery (C4XD) has signed an exclusive worldwide licensing agreement with Sanofi for access to its oral pre-clinical IL-17A inhibitor programme.